ZGNX - Zogenix: Await Q2 Fintepla Revenue LGS Approval Before Jumping Back In
- Since Fintepla's launch, shares of Zogenix have continued to slide. This is, primarily, due to unimpressive Fintepla adoption two quarters in and an underperforming biotechnology sector.
- Last quarter, Fintepla saw 53% quarter-over-quarter growth, with revenues coming in at $12.3M. Zogenix will report Q2 revenues August 9th.
- Management intends to submit an sNDA later this year for Fintepla in Lennox-Gastaut Syndrome, significantly increasing Fintepla's total addressable market.
- Investors should await Q2 ER and FDA-approval before jumping aboard. Risks include management inexecution, Fintepla safety issues, market competition, political headwinds, etc.
For further details see:
Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In